Stockwatch. After Nycomed, next up?
This article was originally published in Scrip
As the first quarter 2011 earnings season dwindles to a close, the bigger draw this week was the announcement that Nycomed is to be acquired by Takeda for €9.6bn (scripintelligence.com, 19 May 2011). This is the second big ticket acquisition of a mid-sized specialty pharmaceutical company by a bigger acquirer in successive weeks. The first was Cephalon which is being acquired by Teva (scripintelligence.com, 6 May 2011).
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.